Telesta Therapeutics Report issue

For profit Phase 1 Phase 3
Founded: Pointe-claire Canada (1979)
Status: Acquired by ProMetic Life Sciences (2016)

Organization Overview

First Clinical Trial
2006
NCT00406068
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (3)

bacille calmette-guerin (1 trial)

mitomycin (mutamycin) (1 trial)

mycobacterial cell wall-dna complex (3 trials)

Drugs in Phase 1 Trials (1)

azacitidine (vidaza) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 3)

Carcinoma in Situ (Phase 3)

Myelodysplastic Syndromes (Phase 1)

Neoplasm Recurrence, Local (Phase 3)

Neoplasms (Phase 3)

Preleukemia (Phase 1)

Recurrence (Phase 3)

Syndrome (Phase 1)

Urinary Bladder Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 4